PIM
ESPR

Platinum Investment Management’s Esperion Therapeutics ESPR Stock Holding History

Platinum Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-840,052
Closed -$1.85M – 120
2024
Q4 		$1.85M Sell
840,052
-252,810
-23% -$590K 0.11% 62
2024
Q3 		$1.8M Sell
1,092,862
-103,664
-9% -$209K 0.08% 69
2024
Q2 		$2.66M Sell
1,196,526
-401,016
-25% -$943K 0.11% 59
2024
Q1 		$4.28M Sell
1,597,542
-1,213,013
-43% -$2.95M 0.17% 47
2023
Q4 		$8.4M Sell
2,810,555
-378,962
-12% -$492K 0.34% 42
2023
Q3 		$3.13M Sell
3,189,517
-280,117
-8% -$405K 0.12% 61
2023
Q2 		$4.82M Buy
3,469,634
+889,059
+34% +$1.24M 0.17% 56
2023
Q1 		$4.1M Buy
2,580,575
+1,150,574
+80% +$5.94M 0.14% 64
2022
Q4 		$8.91M Hold
1,430,001
– – 0.34% 41
2022
Q3 		$9.58M Sell
1,430,001
-193,439
-12% -$1.33M 0.4% 41
2022
Q2 		$10.3M Sell
1,623,440
-1,089,736
-40% -$6.18M 0.39% 40
2022
Q1 		$12.6M Hold
2,713,176
– – 0.39% 39
2021
Q4 		$13.6M Buy
2,713,176
+1,000,000
+58% +$8.01M 0.38% 39
2021
Q3 		$20.6M Hold
1,713,176
– – 0.58% 32
2021
Q2 		$36.2M Buy
1,713,176
+112,563
+7% +$2.71M 0.84% 32
2021
Q1 		$44.9M Buy
1,600,613
+37,744
+2% +$1.11M 1% 29
2020
Q4 		$40.6M Buy
1,562,869
+696,188
+80% +$20.9M 0.93% 30
2020
Q3 		$32.2M Buy
866,681
+15,228
+2% +$603K 0.8% 30
2020
Q2 		$43.7M Buy
851,453
+39,761
+5% +$1.66M 1% 26
2020
Q1 		$25.6M Buy
811,692
+773,238
+2,011% +$40.8M 0.65% 30
2019
Q4 		$2.29M Buy
+38,454
New +$1.73M 0.05% 63

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Platinum Investment Management's ESPR Position: Q1 2025 in Review

Platinum Investment Management sold out of Esperion Therapeutics (ESPR) in Q1 2025, closing a stake of 840,052 shares — an estimated $1.85M sold.

Platinum Investment Management first reported a position in ESPR in Q4 2019 and held it in 21 quarters. The position peaked at $44.9M in Q1 2021. 186 funds tracked by Wall St. Rank hold ESPR as of Q1 2025.

  • Platinum Investment Management reported no remaining Esperion Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Platinum Investment Management sold 840,052 Esperion Therapeutics shares in Q1 2025, an estimated $1.85M.
  • Platinum Investment Management first reported a position in Esperion Therapeutics in Q4 2019 and held it in 21 quarters.
  • Platinum Investment Management's Esperion Therapeutics position peaked at $44.9M in Q1 2021.
  • 186 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2025.

Based on Platinum Investment Management's 13F filing for Q1 2025, filed 15 May 2025.